84290-49-3

Usage

Uses

Used in Pharmaceutical Industry:
2-hydroxy-6-(methoxymethoxy)benzaldehyde is used as a building block for the synthesis of various pharmaceuticals. Its hydroxy and methoxymethoxy groups enable the formation of diverse derivatives with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 2-hydroxy-6-(methoxymethoxy)benzaldehyde serves as a key intermediate in the production of various agrochemicals, contributing to the development of effective and environmentally friendly solutions for crop protection and pest control.
Used in Fine Chemicals Industry:
2-hydroxy-6-(methoxymethoxy)benzaldehyde is utilized as a versatile intermediate in the synthesis of fine chemicals, including specialty chemicals and advanced materials, due to its unique reactivity and functional groups.
Used in Fragrance and Flavor Industry:
As a precursor in the manufacture of fragrances and flavors, 2-hydroxy-6-(methoxymethoxy)benzaldehyde leverages its unique chemical properties to create a wide range of scent and taste profiles for various applications in the perfumery, food, and beverage industries.

Upstream product

• 888958-28-9 5-(methoxymethoxy)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one 
• 79834-12-1 2,6-bis((2-methoxyethoxy)methoxy)benzaldehyde 
• 108-46-3 recorcinol 
• 57234-29-4 1,3-bis(methoxymethyl)resorcinol 
• 6751-75-3 2-bromoresorcinol 
• 155351-64-7 3-(methoxymethoxy)phenyl 2-tetrahydropyranyl ether 
• 18066-10-9 3-methoxymethyloxyphenol 

Downstream Products

• 199388-07-3 4-(2-Formyl-3-methoxymethoxy-phenoxymethyl)-benzoic acid methyl ester 
• 1012338-46-3 C₁₃H₁₄O₅ 
• 1251921-64-8 2-methoxymethoxy-6-(1-(3-phenyluryl-phenyl)ethoxy)-benzaldehyde 
• 1246512-98-0 C₂₂H₂₀N₂O₄ 
• 1446321-46-5 2-hydroxy-6-([2-[1-(propan-2-yl)-1H-pyrazol-5-yl]pyridin-3-yl]methoxy)benzaldehyde 
• 84290-26-6 ethyl 4-(2-formyl-3-hydroxyphenoxymethyl)benzoate 
• 664324-22-5 methyl 4-((2-formyl-3-hydroxyphenoxy)methyl)benzoate 
• 84290-27-7 4-(2-formyl-3-hydroxyphenoxymethyl)benzoic acid 

Relevant academic research and scientific papers

PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VOXELOTOR

The invention relates to a process for the preparation of Voxelotor, or a salt or solvate thereof, according to the following scheme (Formula 1).

Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin

We report the discovery of a new potent allosteric effector of sickle cell hemoglobin, GBT440 (36), that increases the affinity of hemoglobin for oxygen and consequently inhibits its polymerization when subjected to hypoxic conditions. Unlike earlier allosteric activators that bind covalently to hemoglobin in a 2:1 stoichiometry, 36 binds with a 1:1 stoichiometry. Compound 36 is orally bioavailable and partitions highly and favorably into the red blood cell with a RBC/plasma ratio of ～150. This partitioning onto the target protein is anticipated to allow therapeutic concentrations to be achieved in the red blood cell at low plasma concentrations. GBT440 (36) is in Phase 3 clinical trials for the treatment of sickle cell disease (NCT03036813).

CRYSTALLINE 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE ANSOLVATE SALTS

Disclosed are crystalline ansolvate salts of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the hydrochloride Form I.

Crystalline Polymorphs of the Free Base of 2-Hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Disclosed are crystalline free base ansolvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1).

IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION

The present invention provides imidazothiadiazole compounds of Formula (I) wherein A, B, D, Rx, R1, R2, R3, X1, X2 and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments.

The chirality conversion reagent for amino acids based on salicyl aldehyde

2-Hydroxy-6-(1-(3-phenylurylphenyl)ethoxy)-benzaldehyde (2) has been synthesized in racemic form from 1,3-Dihydroxybenzene via formylation and reaction with 3-phenyluryl-methylbenzylbromide. The optically pure form of 2 was separated by normal silica colu

Controlling cis/trans-selectivity in intramolecular Diels-Alder reactions of benzo-tethered, ester linked 1,3,9-decatrienes

Predictions from DFT (B3LYP/6-31 G(d))-computed stereoisomer product distributions for intramolecular Diels-Alder (IMDA) reactions have been successfully replicated in the laboratory. Benzo-tethered hexadienyl acrylates generally undergo moderately trans-

Efficient and selective reduction protocols of the 2,2-dimethyl-1,3- benzodioxan-4-one functional group to readily provide both substituted salicylaldehydes and 2-hydroxybenzyl alcohols

Two complementary procedures have been developed that selectively allow for the synthesis of either substituted salicylaldehydes or the corresponding 2-hydroxylbenzyl alcohols upon treatment of the 2,2-dimethyl-1,3-benzodioxan-4- one functional group with DIBAL-H or LAH, respectively.

Regioselective synthesis of 6-substituted 2-hydroxybenzaldehyde: Efficient synthesis of the immunomodulator tucaresol and related analogues

Two new improved procedures have been developed for the preparation of the immunostimulant tucaresol 1 [4-(2-formyl-3-hydroxyphenoxymethyl)benzoic acid]. These approaches, which start from resorcinol or 2,6-dimethoxybenzaldehyde, are practical and therefore amenable to scale-up. In the case of the second approach, the multi-step synthesis reported in the literature has been reduced to three steps. Furthermore, unlike the reported method, our synthesis is versatile for the preparation of tucaresol analogues. The method is general and applicable for the preparation of 6-substituted 2-hydroxybenzaldehydes.

Pharmaceutical compounds, preparation, use and intermediates therefor and their preparation

This invention is directed to novel ether compounds of formula (I) STR1 which are of value in medicine in the palliation of haemoglobinopathies, in particular sickle-cell anemia, and also in the palliation of pulmonary dyefunction, protection from the effects of hypoxia and the radio-sensitization of tumours. The invention is also directed to methods for the preparation of the ether compounds, to pharmaceutical formulations containing them, the preparation of such formulations and the use of the compounds in human medicine. Also provided by the invention are intermediates of value in the preparation of the ether compounds, by the methods described, and the preparation of the intermediates.